49 related articles for article (PubMed ID: 9477948)
1. Site-specific PEGylation of recombinant tissue-type plasminogen activator.
Meiners K; Hamm P; Gutmann M; Niedens J; Nowak-Król A; Pané S; Lühmann T
Eur J Pharm Biopharm; 2023 Nov; 192():79-87. PubMed ID: 37783360
[TBL] [Abstract][Full Text] [Related]
2. PAI-1 in Diabetes: Pathophysiology and Role as a Therapeutic Target.
Altalhi R; Pechlivani N; Ajjan RA
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33804680
[TBL] [Abstract][Full Text] [Related]
3. Targeting PAI-1 in Cardiovascular Disease: Structural Insights Into PAI-1 Functionality and Inhibition.
Sillen M; Declerck PJ
Front Cardiovasc Med; 2020; 7():622473. PubMed ID: 33415130
[TBL] [Abstract][Full Text] [Related]
4. Chemical Antagonists of Plasminogen Activator Inhibitor-1: Mechanisms of Action and Therapeutic Potential in Vascular Disease.
Simone TM; Higgins SP; Higgins CE; Lennartz MR; Higgins PJ
J Mol Genet Med; 2014 Oct; 8(3):. PubMed ID: 26110015
[No Abstract] [Full Text] [Related]
5. Mechanistic characterization and crystal structure of a small molecule inactivator bound to plasminogen activator inhibitor-1.
Li SH; Reinke AA; Sanders KL; Emal CD; Whisstock JC; Stuckey JA; Lawrence DA
Proc Natl Acad Sci U S A; 2013 Dec; 110(51):E4941-9. PubMed ID: 24297881
[TBL] [Abstract][Full Text] [Related]
6. Low Molecular Weight Antagonists of Plasminogen Activator Inhibitor-1: Therapeutic Potential in Cardiovascular Disease.
Simone TM; Higgins PJ
Mol Med Ther; 2012 Aug; 1(1):101. PubMed ID: 23936868
[TBL] [Abstract][Full Text] [Related]
7. Characterization of a small molecule inhibitor of plasminogen activator inhibitor type 1 that accelerates the transition into the latent conformation.
Fjellström O; Deinum J; Sjögren T; Johansson C; Geschwindner S; Nerme V; Legnehed A; McPheat J; Olsson K; Bodin C; Paunovic A; Gustafsson D
J Biol Chem; 2013 Jan; 288(2):873-85. PubMed ID: 23155046
[TBL] [Abstract][Full Text] [Related]
8. Characterization of a novel class of polyphenolic inhibitors of plasminogen activator inhibitor-1.
Cale JM; Li SH; Warnock M; Su EJ; North PR; Sanders KL; Puscau MM; Emal CD; Lawrence DA
J Biol Chem; 2010 Mar; 285(11):7892-902. PubMed ID: 20061381
[TBL] [Abstract][Full Text] [Related]
9. Serpins in thrombosis, hemostasis and fibrinolysis.
Rau JC; Beaulieu LM; Huntington JA; Church FC
J Thromb Haemost; 2007 Jul; 5 Suppl 1(Suppl 1):102-15. PubMed ID: 17635716
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of plasminogen activator inhibitor-1 binding to endocytosis receptors of the low-density-lipoprotein receptor family by a peptide isolated from a phage display library.
Jensen JK; Malmendal A; Schiøtt B; Skeldal S; Pedersen KE; Celik L; Nielsen NC; Andreasen PA; Wind T
Biochem J; 2006 Nov; 399(3):387-96. PubMed ID: 16813566
[TBL] [Abstract][Full Text] [Related]
11. Biochemical mechanism of action of a diketopiperazine inactivator of plasminogen activator inhibitor-1.
Einholm AP; Pedersen KE; Wind T; Kulig P; Overgaard MT; Jensen JK; Bødker JS; Christensen A; Charlton P; Andreasen PA
Biochem J; 2003 Aug; 373(Pt 3):723-32. PubMed ID: 12723974
[TBL] [Abstract][Full Text] [Related]
12. A redox-sensitive loop regulates plasminogen activator inhibitor type 2 (PAI-2) polymerization.
Wilczynska M; Lobov S; Ohlsson PI; Ny T
EMBO J; 2003 Apr; 22(8):1753-61. PubMed ID: 12682008
[TBL] [Abstract][Full Text] [Related]
13. Plasminogen activator inhibitor-1 polymers, induced by inactivating amphipathic organochemical ligands.
Pedersen KE; Einholm AP; Christensen A; Schack L; Wind T; Kenney JM; Andreasen PA
Biochem J; 2003 Jun; 372(Pt 3):747-55. PubMed ID: 12656676
[TBL] [Abstract][Full Text] [Related]
14. Plasminogen activator inhibitor type-1 (part two): role for failure of thrombolytic therapy. PAI-1 resistance as a potential benefit for new fibrinolytic agents.
Huber K
J Thromb Thrombolysis; 2001 May; 11(3):195-202. PubMed ID: 11577257
[TBL] [Abstract][Full Text] [Related]
15. Topography of a 2.0 A structure of alpha1-antitrypsin reveals targets for rational drug design to prevent conformational disease.
Elliott PR; Pei XY; Dafforn TR; Lomas DA
Protein Sci; 2000 Jul; 9(7):1274-81. PubMed ID: 10933492
[TBL] [Abstract][Full Text] [Related]
16. Identification of the binding site for a low-molecular-weight inhibitor of plasminogen activator inhibitor type 1 by site-directed mutagenesis.
Björquist P; Ehnebom J; Inghardt T; Hansson L; Lindberg M; Linschoten M; Strömqvist M; Deinum J
Biochemistry; 1998 Feb; 37(5):1227-34. PubMed ID: 9477948
[TBL] [Abstract][Full Text] [Related]
17. The variable region-1 from tissue-type plasminogen activator confers specificity for plasminogen activator inhibitor-1 to thrombin by facilitating catalysis: release of a kinetic block by a heterologous protein surface loop.
Dekker RJ; Eichinger A; Stoop AA; Bode W; Pannekoek H; Horrevoets AJ
J Mol Biol; 1999 Oct; 293(3):613-27. PubMed ID: 10543954
[TBL] [Abstract][Full Text] [Related]
18. Plasminogen activator inhibitor 1 contains a cryptic high affinity receptor binding site that is exposed upon complex formation with tissue-type plasminogen activator.
Horn IR; van den Berg BM; Moestrup SK; Pannekoek H; van Zonneveld AJ
Thromb Haemost; 1998 Nov; 80(5):822-8. PubMed ID: 9843178
[TBL] [Abstract][Full Text] [Related]
19. Different structural requirements for plasminogen activator inhibitor 1 (PAI-1) during latency transition and proteinase inhibition as evidenced by phage-displayed hypermutated PAI-1 libraries.
Stoop AA; Eldering E; Dafforn TR; Read RJ; Pannekoek H
J Mol Biol; 2001 Jan; 305(4):773-83. PubMed ID: 11162091
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
